{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T10:57:07Z","timestamp":1791284227802,"version":"4.1.0"},"reference-count":128,"publisher":"Croatian Society for Medical Biochemistry and Laboratory Medicine","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biochem. med. (Online)"],"published-print":{"date-parts":[[2026,10,15]]},"abstract":"<jats:p>Personalised medicine has become a central paradigm in modern healthcare, aiming to tailor prevention, diagnosis, and therapy to each patient\u2019s unique molecular and clinical profile. This paper provides a comprehensive overview of the lectures presented at the 36th annual Symposium of the Croatian society of medical biochemistry and laboratory medicine. It highlights key topics including the role of disease-causing variants in hereditary disorders, the development of cystic fibrosis transmembrane conductance regulator (CFTR) modulators, the evolution of newborn screening programs and spinal muscular atrophy diagnostics, emphasizing early detection and timely initiation of therapy, advances in cancer genetics, pharmacogenetics, and the translation of other laboratory-based innovations into clinical practice. Altogether, these advances reaffirm the central role of laboratory diagnostics as the cornerstone of personalised medicine, bridging genetic discovery with clinical translation and transforming modern healthcare into a predictive, preventive, and truly patient-centred discipline.<\/jats:p>","DOI":"10.11613\/bm.2026.030501","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T07:06:16Z","timestamp":1786691176000},"page":"408-430","source":"Crossref","is-referenced-by-count":0,"title":["Laboratory diagnostics in personalised medicine - 36th Symposium of the Croatian society of medical biochemistry and laboratory medicine"],"prefix":"10.11613","volume":"36","author":[{"given":"Dunja","family":"Rogi\u0107","sequence":"first","affiliation":[{"name":"Faculty of Pharmacy and Biochemistry","place":["Zagreb"]},{"name":"Department of Laboratory Diagnostics, University Hospital Centre Zagreb","place":["Zagreb"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livija","family":"\u0160imi\u010devi\u0107","sequence":"additional","affiliation":[{"name":"Department of Laboratory Diagnostics, University Hospital Centre Zagreb","place":["Zagreb"]},{"name":"School of Medicine, University of Zagreb","place":["Zagreb"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lana","family":"Ganoci","sequence":"additional","affiliation":[{"name":"Department of Laboratory Diagnostics, University Hospital Centre Zagreb","place":["Zagreb"]},{"name":"School of Medicine, University of Zagreb","place":["Zagreb"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"\u017divkovi\u0107","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Zagreb","place":["Zagreb"]},{"name":"Department of Psychiatry and Psychological Medicine, Zagreb University Hospital Centre","place":["Zagreb"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alma","family":"Mihaljevi\u0107-Pele\u0161","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Zagreb","place":["Zagreb"]},{"name":"Department of Psychiatry and Psychological Medicine, Zagreb University Hospital Centre","place":["Zagreb"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"\u017digman","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Zagreb","place":["Zagreb"]},{"name":"Department of Pediatrics, University Hospital Centre Zagre","place":["Zagreb"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Bambir","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University Hospital Centre Zagre","place":["Zagreb"]},{"name":"Cystic Fibrosis Centre for Children and Adults, University Hospital Centre Zagreb","place":["Zagreb"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Vuki\u0107 Dugac","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Zagreb","place":["Zagreb"]},{"name":"Cystic Fibrosis Centre for Children and Adults, University Hospital Centre Zagreb","place":["Zagreb"]},{"name":"Clinic for respiratory diseases Jordanovac, University Hospital Centre Zagreb","place":["Zagreb"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Du\u0161ka","family":"Tje\u0161i\u0107-Drinkovi\u0107","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Zagreb","place":["Zagreb"]},{"name":"Department of Pediatrics, University Hospital Centre Zagreb","place":["Zagreb"]},{"name":"Cystic Fibrosis Centre for Children and Adults, University Hospital Centre Zagreb","place":["Zagreb"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ksenija","family":"Fumi\u0107","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy and Biochemistry","place":["Zagreb"]},{"name":"Department of Laboratory Diagnostics, University Hospital Centre Zagreb","place":["Zagreb"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Lehman","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University Hospital Centre Zagreb","place":["Zagreb"]},{"name":"Cystic Fibrosis Centre for Children and Adults, University Hospital Centre Zagreb","place":["Zagreb"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Rako","sequence":"additional","affiliation":[{"name":"Department of Laboratory Diagnostics, University Hospital Centre Zagreb","place":["Zagreb"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Popovi\u0107","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Zagreb","place":["Zagreb"]},{"name":"Department of Oncology, University Hospital Centre Zagreb","place":["Zagreb"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4885","published-online":{"date-parts":[[2026,10,15]]},"reference":[{"key":"key20260814070612_r1","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.jval.2013.06.005","article-title":"The faces of personalized medicine: a framework for understanding its meaning and scope.","volume":"16","author":"Redekop","year":"2013","journal-title":"Value Health"},{"key":"key20260814070612_r2","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.trsl.2009.09.005","article-title":"Genomic and personalized medicine: foundations and applications.","volume":"154","author":"Ginsburg","year":"2009","journal-title":"Transl Res"},{"key":"key20260814070612_r3","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/joim.13698","article-title":"Implementation of precision medicine in healthcare\u2014A European perspective.","volume":"294","author":"Stenzinger","year":"2023","journal-title":"J Intern Med"},{"key":"key20260814070612_r4","doi-asserted-by":"crossref","first-page":"e432","DOI":"10.1634\/theoncologist.2019-0054","article-title":"Twenty Years with Personalized Medicine: Past, Present, and Future of Individualized Pharmacotherapy.","volume":"24","author":"J\u00f8rgensen","year":"2019","journal-title":"Oncologist"},{"key":"key20260814070612_r5","doi-asserted-by":"crossref","first-page":"194","DOI":"10.2174\/1389201018666170224105600","article-title":"Clinical Applications of Personalized Medicine: A New Paradigm and Challenge.","volume":"18","author":"Di Sanzo","year":"2017","journal-title":"Curr Pharm Biotechnol"},{"key":"key20260814070612_r6","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1146\/annurev-genom-082410-101446","article-title":"Personalized Medicine: Progress and Promise.","volume":"12","author":"Chan","year":"2011","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"key20260814070612_r7","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju321","article-title":"Words Matter: Distinguishing \u201cPersonalized Medicine\u201d and \u201cBiologically Personalized Therapeutics\u201d.","volume":"106","author":"Cherny","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"key20260814070612_r8","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/bs.pmbts.2024.02.007","article-title":"Drug repurposing for personalized medicine.","volume":"207","author":"Hora","year":"2024","journal-title":"Prog Mol Biol Transl Sci"},{"key":"key20260814070612_r9","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2020.569175","article-title":"Milestones in Personalized Medicine: From the Ancient Time to Nowadays\u2014the Provocation of COVID-19.","volume":"11","author":"Visvikis-Siest","year":"2020","journal-title":"Front Genet"},{"key":"key20260814070612_r10","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/171737a0","article-title":"Molecular Structure of Nucleic Acids: A Structure for Deoxyribose Nucleic Acid.","volume":"171","author":"Watson","year":"1953","journal-title":"Nature"},{"key":"key20260814070612_r11","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/171740a0","article-title":"Molecular Configuration in Sodium Thymonucleate.","volume":"171","author":"Franklin","year":"1953","journal-title":"Nature"},{"key":"key20260814070612_r12","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1001\/jama.2023.8120","article-title":"Cystic Fibrosis: A Review.","volume":"329","author":"Ong","year":"2023","journal-title":"JAMA"},{"key":"key20260814070612_r13","doi-asserted-by":"crossref","first-page":"15010","DOI":"10.1038\/nrdp.2015.10","article-title":"Cystic fibrosis.","volume":"1","author":"Ratjen","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"key20260814070612_r14","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1164\/rccm.202011-4153OC","article-title":"Rapid Improvement after Starting Elexacaftor-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease.","volume":"204","author":"Burgel","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"key20260814070612_r15","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02029-2022","article-title":"Long-term safety and efficacy of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from a 192-week open-label extension study.","volume":"62","author":"Daines","year":"2023","journal-title":"Eur Respir J"},{"key":"key20260814070612_r16","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0045-2024","article-title":"New drugs, new challenges in cystic fibrosis care.","volume":"33","author":"Fajac","year":"2024","journal-title":"Eur Respir Rev."},{"key":"key20260814070612_r17","first-page":"27","article-title":"Cisti\u010dna fibroza \u2013 nove terapijske mogu\u0107nosti.","volume":"144","author":"Tje\u0161i\u0107-Drinkovi\u0107","year":"2022","journal-title":"Lijec Vjesn"},{"key":"key20260814070612_r18","first-page":"121","article-title":"Cisti\u010dna fibroza \u2013 ishodi lije\u010denja u Hrvatskoj uz CFTR modulatore.","volume":"145","author":"Tje\u0161i\u0107-Drinkovi\u0107","year":"2023","journal-title":"Lijec Vjesn"},{"key":"key20260814070612_r19","unstructured":"Zolin A, Adamoli A, Bakkeheim E. ECFSPR Annual Report 2023. European Cystic Fibrosis Society [Internet]. [cited 2025 Oct 3]. Available from: https:\/\/www.ecfs.eu\/projects\/ecfs-patient-registry\/annual-reports"},{"key":"key20260814070612_r20","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.nbt.2012.03.004","article-title":"A personal view on systems medicine and the emergence of proactive P4 medicine: predictive, preventive, personalized and participatory.","volume":"29","author":"Hood","year":"2012","journal-title":"N Biotechnol"},{"key":"key20260814070612_r21","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/ajmg.c.32029","article-title":"Are we prepared to deliver gene-targeted therapies for rare diseases?","volume":"193","author":"Yu","year":"2023","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"key20260814070612_r22","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ymgme.2014.07.019","article-title":"Fifty years of phenylketonuria newborn screening - A great success for many, but what about the rest?","volume":"113","author":"Groselj","year":"2014","journal-title":"Mol Genet Metab"},{"key":"key20260814070612_r23","first-page":"318","article-title":"Principles and practice of screening for disease.","volume":"16","author":"Wilson","year":"1968","journal-title":"J R Coll Gen Pract"},{"key":"key20260814070612_r24","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2471\/BLT.07.050112","article-title":"Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years.","volume":"86","author":"Andermann","year":"2008","journal-title":"Bull World Health Organ"},{"key":"key20260814070612_r25","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3390\/ijns10030062","article-title":"Wilson and Jungner Revisited: Are Screening Criteria Fit for the 21st Century?","volume":"10","author":"Schnabel-Besson","year":"2024","journal-title":"Int J Neonatal Screen"},{"key":"key20260814070612_r26","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3390\/ijns10020038","article-title":"Current Status of Newborn Bloodspot Screening Worldwide 2024: A Comprehensive Review of Recent Activities (2020-2023).","volume":"10","author":"Therrell","year":"2024","journal-title":"Int J Neonatal Screen"},{"key":"key20260814070612_r27","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s10545-014-9688-5","article-title":"50 years of newborn screening.","volume":"37","author":"Hoffmann","year":"2014","journal-title":"J Inherit Metab Dis"},{"key":"key20260814070612_r28","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/gim.2014.117","article-title":"Development of DNA confirmatory and high-risk diagnostic testing for newborns using targeted next-generation DNA sequencing.","volume":"17","author":"Bhattacharjee","year":"2015","journal-title":"Genet Med."},{"key":"key20260814070612_r29","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3390\/ijns10030050","article-title":"One-Year Pilot Study Results of Newborn Screening for Spinal Muscular Atrophy in the Republic of Croatia.","volume":"10","author":"\u0160imi\u0107","year":"2024","journal-title":"Int J Neonatal Screen"},{"key":"key20260814070612_r30","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/jimd.12650","article-title":"Genomic newborn screening: Are we entering a new era of screening?","volume":"46","author":"Spiekerkoetter","year":"2023","journal-title":"J Inherit Metab Dis"},{"key":"key20260814070612_r31","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1002\/jimd.12750","article-title":"Comparative analysis of gene and disease selection in genomic newborn screening studies.","volume":"47","author":"Betzler","year":"2024","journal-title":"J Inherit Metab Dis"},{"key":"key20260814070612_r32","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2022.865400","article-title":"Exome\/Genome-Wide Testing in Newborn Screening: A Proportionate Path Forward.","volume":"13","author":"Rahimzadeh","year":"2022","journal-title":"Front Genet"},{"key":"key20260814070612_r33","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s10545-017-0130-7","article-title":"Promises and pitfalls of untargeted metabolomics.","volume":"41","author":"Gertsman","year":"2018","journal-title":"J Inherit Metab Dis"},{"key":"key20260814070612_r34","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13023-022-02231-x","article-title":"Application of a next-generation sequencing (NGS) panel in newborn screening efficiently identifies inborn disorders of neonates.","volume":"17","author":"Huang","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"key20260814070612_r35","doi-asserted-by":"crossref","DOI":"10.1016\/j.gim.2024.101077","article-title":"Gene selection for genomic newborn screening: Moving toward consensus?","volume":"26","author":"Downie","year":"2024","journal-title":"Genet Med."},{"key":"key20260814070612_r36","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3390\/ijns10030042","article-title":"The Multi-Omic Approach to Newborn Screening: Opportunities and Challenges.","volume":"10","author":"Ashenden","year":"2024","journal-title":"Int J Neonatal Screen"},{"key":"key20260814070612_r37","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1002\/ajmg.a.33474","article-title":"Newborn and carrier screening for spinal muscular atrophy.","volume":"152A","author":"Prior","year":"2010","journal-title":"Am J Med Genet A"},{"key":"key20260814070612_r38","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1750-1172-6-71","article-title":"Spinal muscular atrophy.","volume":"6","author":"D\u2019Amico","year":"2011","journal-title":"Orphanet J Rare Dis"},{"key":"key20260814070612_r39","doi-asserted-by":"crossref","first-page":"7896","DOI":"10.3390\/ijms22157896","article-title":"Genomic Variability in the Survival Motor Neuron Genes (SMN1 and SMN2): Implications for Spinal Muscular Atrophy Phenotype and Therapeutics Development.","volume":"22","author":"Butchbach","year":"2021","journal-title":"Int J Mol Sci"},{"key":"key20260814070612_r40","article-title":"Spinal muscular atrophy: From approved therapies to future therapeutic targets for personalized medicine.","volume":"2","author":"Chaytow","year":"2021","journal-title":"Cell Rep Med"},{"key":"key20260814070612_r41","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/s41582-020-00410-7","article-title":"Spinal muscular atrophy - the dawning of a new era.","volume":"16","author":"Farrar","year":"2020","journal-title":"Nat Rev Neurol"},{"key":"key20260814070612_r42","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/ana.24864","article-title":"Emerging therapies and challenges in spinal muscular atrophy.","volume":"81","author":"Farrar","year":"2017","journal-title":"Ann Neurol"},{"key":"key20260814070612_r43","doi-asserted-by":"crossref","first-page":"14873","DOI":"10.3390\/ijms241914873","article-title":"Spinal Muscular Atrophy: An Evolving Scenario through New Perspectives in Diagnosis and Advances in Therapies.","volume":"24","author":"Angilletta","year":"2023","journal-title":"Int J Mol Sci"},{"key":"key20260814070612_r44","doi-asserted-by":"crossref","first-page":"9029","DOI":"10.3390\/ijms22169029","article-title":"The Importance of Digging into the Genetics of SMN Genes in the Therapeutic Scenario of Spinal Muscular Atrophy.","volume":"22","author":"Costa-Roger","year":"2021","journal-title":"Int J Mol Sci"},{"key":"key20260814070612_r45","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","article-title":"Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study.","volume":"29","author":"De Vivo","year":"2019","journal-title":"Neuromuscul Disord"},{"key":"key20260814070612_r46","first-page":"1829","article-title":"Parental Burden and Quality of Life in 5q-SMA Diagnosed by Newborn Screening.","volume":"9","author":"K\u00f6lbel","year":"2022","journal-title":"Children (Basel)"},{"key":"key20260814070612_r47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpn.2022.04.006","article-title":"Mid- and long-term (at least 12 months) follow-up of patients with spinal muscular atrophy (SMA) treated with nusinersen, onasemnogene abeparvovec, risdiplam or combination therapies: A systematic review of real-world study data.","volume":"39","author":"Erdos","year":"2022","journal-title":"Eur J Paediatr Neurol"},{"key":"key20260814070612_r48","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1158\/1078-0432.CCR-17-0465","article-title":"Recommendations for Childhood Cancer Screening and Surveillance in DNA Repair Disorders.","volume":"23","author":"Walsh","year":"2017","journal-title":"Clin Cancer Res"},{"key":"key20260814070612_r49","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2020.570084","article-title":"DNA Repair Syndromes and Cancer: Insights Into Genetics and Phenotype Patterns.","volume":"8","author":"Sharma","year":"2020","journal-title":"Front Pediatr"},{"key":"key20260814070612_r50","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.annonc.2022.07.008","article-title":"Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancers.","volume":"33","author":"Jahn","year":"2022","journal-title":"Ann Oncol"},{"key":"key20260814070612_r51","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1200\/JCO.2005.10.042","article-title":"Hereditary Cancer Predisposition Syndromes.","volume":"23","author":"Garber","year":"2005","journal-title":"J Clin Oncol"},{"key":"key20260814070612_r52","doi-asserted-by":"crossref","first-page":"40","DOI":"10.5306\/wjco.v14.i2.40","article-title":"Hereditary cancer syndromes.","volume":"14","author":"Imyanitov","year":"2023","journal-title":"World J Clin Oncol"},{"key":"key20260814070612_r53","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/imj.14394","article-title":"Multiple endocrine neoplasia: an update.","volume":"49","author":"McDonnell","year":"2019","journal-title":"Intern Med J"},{"key":"key20260814070612_r54","doi-asserted-by":"crossref","first-page":"4255","DOI":"10.1200\/JCO.2009.25.7816","article-title":"Genome-Wide Association Studies of Cancer.","volume":"28","author":"Stadler","year":"2010","journal-title":"J Clin Oncol"},{"key":"key20260814070612_r55","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"key":"key20260814070612_r56","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1002\/humu.20880","article-title":"Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results.","volume":"29","author":"Plon","year":"2008","journal-title":"Hum Mutat"},{"key":"key20260814070612_r57","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/nbt1486","article-title":"Next-generation DNA sequencing.","volume":"26","author":"Shendure","year":"2008","journal-title":"Nat Biotechnol"},{"key":"key20260814070612_r58","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1146\/annurev-genom-083115-022413","article-title":"Advancements in Next-Generation Sequencing.","volume":"17","author":"Levy","year":"2016","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"key20260814070612_r59","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.3390\/genes14051025","article-title":"Hereditary Cancer Syndromes: A Comprehensive Review with a Visual Tool.","volume":"14","author":"Garutti","year":"2023","journal-title":"Genes (Basel)"},{"key":"key20260814070612_r60","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in Microsatellite-Instability\u2013High Advanced Colorectal Cancer.","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N Engl J Med"},{"key":"key20260814070612_r61","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.","volume":"377","author":"Robson","year":"2017","journal-title":"N Engl J Med"},{"key":"key20260814070612_r62","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1053\/j.gastro.2022.08.058","article-title":"Lynch Syndrome Genetics and Clinical Implications.","volume":"164","author":"Peltom\u00e4ki","year":"2023","journal-title":"Gastroenterology"},{"key":"key20260814070612_r63","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.suc.2022.08.016","article-title":"Genetics of Breast Cancer: Risk Models, Who to Test, and Management Options.","volume":"103","author":"Rooney","year":"2023","journal-title":"Surg Clin North Am"},{"key":"key20260814070612_r64","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2022.867226","article-title":"The Impact of Proband Indication for Genetic Testing on the Uptake of Cascade Testing Among Relatives.","volume":"13","author":"Schmidlen","year":"2022","journal-title":"Front Genet"},{"key":"key20260814070612_r65","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.1200\/JCO.22.00303","article-title":"Cascade Testing for Hereditary Cancer Syndromes: Should We Move Toward Direct Relative Contact? A Systematic Review and Meta-Analysis.","volume":"40","author":"Frey","year":"2022","journal-title":"J Clin Oncol"},{"key":"key20260814070612_r66","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1126\/science.1235122","article-title":"Cancer genome landscapes.","volume":"339","author":"Vogelstein","year":"2013","journal-title":"Science"},{"key":"key20260814070612_r67","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cell.2013.03.002","article-title":"Lessons from the Cancer Genome.","volume":"153","author":"Garraway","year":"2013","journal-title":"Cell"},{"key":"key20260814070612_r68","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41586-020-1969-6","article-title":"Pan-cancer analysis of whole genomes.","volume":"578","author":"Aaltonen","year":"2020","journal-title":"Nature"},{"key":"key20260814070612_r69","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.cell.2017.09.042","article-title":"Universal Patterns of Selection in Cancer and Somatic Tissues.","volume":"171","author":"Martincorena","year":"2017","journal-title":"Cell"},{"key":"key20260814070612_r70","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.59629","article-title":"Use of signals of positive and negative selection to distinguish cancer genes and passenger genes.","volume":"10","author":"B\u00e1nyai","year":"2021","journal-title":"eLife"},{"key":"key20260814070612_r71","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.cell.2020.01.032","article-title":"Passenger mutations in 2500 cancer genomes: Overall molecular functional impact and consequences.","volume":"180","author":"Kumar","year":"2020","journal-title":"Cell"},{"key":"key20260814070612_r72","unstructured":"PDQ\u00ae Cancer Genetics Editorial Board. PDQ Genetics of Breast and Gynecologic Cancers. Bethesda, MD: National Cancer Institute. Updated 03\/06\/2025. [Internet]. [cited 2025 Oct 15]. Available at: https:\/\/www.cancer.gov\/types\/breast\/hp\/breast-ovarian-genetics-pdq"},{"key":"key20260814070612_r73","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1113205","article-title":"Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.","volume":"366","author":"Gerlinger","year":"2012","journal-title":"N Engl J Med"},{"key":"key20260814070612_r74","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa1616288","article-title":"Tracking the Evolution of Non-Small-Cell Lung Cancer.","volume":"376","author":"Jamal-Hanjani","year":"2017","journal-title":"N Engl J Med"},{"key":"key20260814070612_r75","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/nrclinonc.2017.14","article-title":"Integrating liquid biopsies into the management of cancer.","volume":"14","author":"Siravegna","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"key20260814070612_r76","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nrg.2016.49","article-title":"Coming of age: ten years of next-generation sequencing technologies.","volume":"17","author":"Goodwin","year":"2016","journal-title":"Nat Rev Genet"},{"key":"key20260814070612_r77","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13073-016-0350-8","article-title":"Germline, hematopoietic, mosaic, and somatic variation: interplay between inherited and acquired genetic alterations in disease assessment.","volume":"8","author":"Konnick","year":"2016","journal-title":"Genome Med"},{"key":"key20260814070612_r78","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer.","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"key20260814070612_r79","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1158\/1078-0432.CCR-20-3054","article-title":"Tumor Mutational Burden as a Predictor of Immunotherapy Response: Is More Always Better?","volume":"27","author":"Strickler","year":"2021","journal-title":"Clin Cancer Res"},{"key":"key20260814070612_r80","first-page":"155","article-title":"Targeted Cancer Therapies.","volume":"103","author":"Smith","year":"2021","journal-title":"Am Fam Physician"},{"key":"key20260814070612_r81","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.21037\/atm-22-356","article-title":"Challenges, opportunities, and innovative statistical designs for precision oncology trials.","volume":"10","author":"Yin","year":"2022","journal-title":"Ann Transl Med"},{"key":"key20260814070612_r82","doi-asserted-by":"crossref","first-page":"9","DOI":"10.6004\/jadpro.2023.14.3.16","article-title":"Biomarker-Driven Oncology Clinical Trials: Novel Designs in the Era of Precision Medicine.","volume":"14","author":"Moore","year":"2023","journal-title":"J Adv Pract Oncol"},{"key":"key20260814070612_r83","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13073-022-01102-1","article-title":"Clinical trial design in the era of precision medicine.","volume":"14","author":"Fountzilas","year":"2022","journal-title":"Genome Med"},{"key":"key20260814070612_r84","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1146\/annurev.pharmtox.37.1.269","article-title":"Molecular mechanisms of genetic polymorphisms of drug metabolism.","volume":"37","author":"Meyer","year":"1997","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"10197","key":"key20260814070612_r85","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0140-6736(19)31276-0","article-title":"Pharmacogenomics.","volume":"394","author":"Roden","year":"2019","journal-title":"Lancet"},{"key":"key20260814070612_r86","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/s41576-022-00572-8","article-title":"Pharmacogenomics: current status and future perspectives.","volume":"24","author":"Pirmohamed","year":"2023","journal-title":"Nat Rev Genet"},{"key":"key20260814070612_r87","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1124\/pharmrev.122.000810","article-title":"Pharmacogenomics: Driving Personalized Medicine.","volume":"75","author":"Sadee","year":"2023","journal-title":"Pharmacol Rev"},{"key":"key20260814070612_r88"},{"key":"key20260814070612_r89","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1146\/annurev-genom-111621-102737","article-title":"Advancing Pharmacogenomics from Single-Gene to Preemptive Testing.","volume":"23","author":"Haidar","year":"2022","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"key20260814070612_r90","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1189976","article-title":"Pharmacogenomics in practice: a review and implementation guide.","volume":"14","author":"Kabbani","year":"2023","journal-title":"Front Pharmacol"},{"key":"key20260814070612_r91","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0140-6736(22)01841-4","article-title":"A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study.","volume":"401","author":"Swen","year":"2023","journal-title":"Lancet"},{"key":"key20260814070612_r92","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1146\/annurev-pharmtox-051921-091209","article-title":"Pharmacogenomics Beyond Single Common Genetic Variants: The Way Forward.","volume":"64","author":"Lauschke","year":"2024","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"key20260814070612_r93","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/j.mayocp.2017.09.001","article-title":"Pharmacogenomics: Precision Medicine and Drug Response.","volume":"92","author":"Weinshilboum","year":"2017","journal-title":"Mayo Clin Proc"},{"key":"key20260814070612_r94","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.gim.2021.12.009","article-title":"Clinical pharmacogenomic testing and reporting: A technical standard of the American College of Medical Genetics and Genomics (ACMG).","volume":"24","author":"Tayeh","year":"2022","journal-title":"Genet Med"},{"key":"key20260814070612_r95","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/clpt.2011.34","article-title":"Pharmacogenetics: from bench to byte--an update of guidelines.","volume":"89","author":"Swen","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"key20260814070612_r96","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/978-1-62703-435-7_20","article-title":"PharmGKB: the Pharmacogenomics Knowledge Base.","volume":"1015","author":"Thorn","year":"2013","journal-title":"Methods Mol Biol"},{"key":"key20260814070612_r97","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2478\/10004-1254-60-2009-1885","article-title":"Genetic polymorphism of metabolic enzymes P450 (CYP) as a susceptibility factor for drug response, toxicity, and cancer risk.","volume":"60","author":"Bozina","year":"2009","journal-title":"Arh Hig Rada Toksikol"},{"key":"key20260814070612_r98","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s00204-020-02971-4","article-title":"Human Family 1\u20134 cytochrome P450 enzymes involved in the metabolic activation of xenobiotic and physiological chemicals: an update.","volume":"95","author":"Rendic","year":"2021","journal-title":"Arch Toxicol"},{"key":"key20260814070612_r99","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/gim.2016.87","article-title":"Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC).","volume":"19","author":"Caudle","year":"2017","journal-title":"Genet Med"},{"key":"key20260814070612_r100","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/cpt.2557","article-title":"The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms.","volume":"111","author":"Cooper-DeHoff","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"key20260814070612_r101","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/cpt.3458","article-title":"Value of Pharmacogenetic Testing Assessed with Real-World Drug Utilization and Genotype Data.","volume":"117","author":"Litonius","year":"2025","journal-title":"Clin Pharmacol Ther"},{"key":"key20260814070612_r102","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3325\/cmj.2020.61.147","article-title":"Use of pharmacogenomics in elderly patients treated for cardiovascular diseases.","volume":"61","author":"Bo\u017eina","year":"2020","journal-title":"Croat Med J"},{"key":"key20260814070612_r103","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1177\/1060028020983049","article-title":"Characterization of Pharmacogenetic Information in Food and Drug Administration Drug Labeling and the Table of Pharmacogenetic Associations.","volume":"55","author":"Cheng","year":"2021","journal-title":"Ann Pharmacother"},{"key":"key20260814070612_r104","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1002\/cpt.1720","article-title":"Evaluation of Current Regulation and Guidelines of Pharmacogenomic Drug Labels: Opportunities for Improvements.","volume":"107","author":"Shekhani","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"key20260814070612_r105","first-page":"6","article-title":"ADME Gene-Related Pharmacogenomic Labeling of FDA-Approved Drugs: Comparison with Clinical Pharmacogenetics Implementation Consortium (CPIC) Evidence Levels.","volume":"11","author":"Deb","year":"2024","journal-title":"Medicines (Basel)"},{"key":"key20260814070612_r106","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00439-021-02385-x","article-title":"Population pharmacogenomics: an update on ethnogeographic differences and opportunities for precision public health.","volume":"141","author":"Zhou","year":"2022","journal-title":"Hum Genet"},{"key":"key20260814070612_r107","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s10549-019-05271-3","article-title":"Global prevalence of depression among breast cancer patients: a systematic review and meta-analysis.","volume":"176","author":"Pilevarzadeh","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"key20260814070612_r108","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.1002\/cncr.29059","article-title":"Overview of breast cancer collaborative stage data items--their definitions, quality, usage, and clinical implications: a review of SEER data for 2004-2010.","volume":"120","author":"Howlader","year":"2014","journal-title":"Cancer"},{"key":"key20260814070612_r109","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1158\/1078-0432.CCR-16-1779","article-title":"Significant Effect of Polymorphisms in CYP2D6 on Response to Tamoxifen Therapy for Breast Cancer: A Prospective Multicenter Study.","volume":"23","author":"Zembutsu","year":"2017","journal-title":"Clin Cancer Res"},{"key":"key20260814070612_r110","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1200\/JCO.2009.25.7246","article-title":"Significant Effect of Polymorphisms in CYP2D6 and ABCC2 on Clinical Outcomes of Adjuvant Tamoxifen Therapy for Breast Cancer Patients.","volume":"28","author":"Kiyotani","year":"2010","journal-title":"J Clin Oncol"},{"key":"key20260814070612_r111","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/sj.clpt.6100406","article-title":"The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype.","volume":"83","author":"Gaedigk","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"key20260814070612_r112","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jmoldx.2016.01.003","article-title":"Preemptive Pharmacogenomic Testing for Precision Medicine: A Comprehensive Analysis of Five Actionable Pharmacogenomic Genes Using Next-Generation DNA Sequencing and a Customized CYP2D6 Genotyping Cascade.","volume":"18","author":"Ji","year":"2016","journal-title":"J Mol Diagn JMD."},{"key":"key20260814070612_r113","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/00008571-200008000-00010","article-title":"CYP2D6 genotypes in a Japanese population: low frequencies of CYP2D6 gene duplication but high frequency of CYP2D6*10.","volume":"10","author":"Nishida","year":"2000","journal-title":"Pharmacogenetics"},{"key":"key20260814070612_r114","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1517\/14622416.3.2.229","article-title":"CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants.","volume":"3","author":"Bradford","year":"2002","journal-title":"Pharmacogenomics"},{"key":"key20260814070612_r115","doi-asserted-by":"crossref","first-page":"5429","DOI":"10.2147\/OTT.S149197","article-title":"The effect of CYP2D6 *10 polymorphism on adjuvant tamoxifen in Asian breast cancer patients: a meta-analysis.","volume":"10","author":"Lu","year":"2017","journal-title":"Onco Targets Ther"},{"key":"key20260814070612_r116","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.1200\/JCO.2007.12.2705","article-title":"Breast Cancer Treatment Outcome With Adjuvant Tamoxifen Relative to Patient CYP2D6 and CYP2C19 Genotypes.","volume":"25","author":"Schroth","year":"2007","journal-title":"J Clin Oncol"},{"key":"key20260814070612_r117","first-page":"103","article-title":"CYP2D6-inhibiting medication use and inherited CYP2D6 variation in relation to adverse breast cancer outcomes after tamoxifen therapy.","volume":"30","author":"Mayer","year":"2019","journal-title":"Cancer Causes Control"},{"key":"key20260814070612_r118","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1093\/jnci\/djg108","article-title":"Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.","volume":"95","author":"Stearns","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"key20260814070612_r119","doi-asserted-by":"crossref","first-page":"582","DOI":"10.3389\/fphar.2017.00582","article-title":"Improved Prediction of Endoxifen Metabolism by CYP2D6 Genotype in Breast Cancer Patients Treated with Tamoxifen.","volume":"8","author":"Schroth","year":"2017","journal-title":"Front Pharmacol"},{"key":"key20260814070612_r120","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1080\/17425255.2022.2160317","article-title":"CYP2D6 pharmacogenetics and phenoconversion in personalized medicine.","volume":"18","author":"Nahid","year":"2022","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"key20260814070612_r121","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/cpt.1007","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy.","volume":"103","author":"Goetz","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"key20260814070612_r122","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1093\/jnci\/dji005","article-title":"CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.","volume":"97","author":"Jin","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"key20260814070612_r123","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.clpt.2006.03.013","article-title":"Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment.","volume":"80","author":"Borges","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"key20260814070612_r124","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1200\/JCO.2009.23.8931","article-title":"Coprescription of Tamoxifen and Medications That Inhibit CYP2D6.","volume":"28","author":"Sideras","year":"2010","journal-title":"J Clin Oncol"},{"key":"key20260814070612_r125","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s10549-025-07644-3","article-title":"The impact of coadministration of venlafaxine, citalopram or gabapentin on the metabolic activation of tamoxifen.","volume":"211","author":"Safgren","year":"2025","journal-title":"Breast Cancer Res Treat"},{"key":"key20260814070612_r126","first-page":"125","article-title":"Breast cancer recurrence in relation to antidepressant use.","volume":"27","author":"Chubak","year":"2016","journal-title":"Cancer Causes Control"},{"key":"key20260814070612_r127","unstructured":"ClinPGx [Internet]. [cited 2025 Oct 15]. The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group. Annotation of DPWG Guideline for tamoxifen and CYP2D6. November 2018 Update. Available from: https:\/\/www.clinpgx.org\/guidelineAnnotation\/PA166104966\/annotation"},{"key":"key20260814070612_r128","unstructured":"CYP2D6 Phenoconversion Calculator. Precision Medicine Program. UF Health. University of Florida [Internet]. [cited 2025 Oct 15]. Available from: https:\/\/precisionmedicine.ufhealth.org\/how-to-interpret-results\/phenoconversion-calculator\/."}],"container-title":["Biochemia medica"],"original-title":[],"link":[{"URL":"https:\/\/hrcak.srce.hr\/file\/507523","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T10:47:22Z","timestamp":1791283642000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.biochemia-medica.com\/en\/journal\/36\/3\/10.11613\/BM.2026.030501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,15]]},"references-count":128,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,10,5]]},"published-print":{"date-parts":[[2026,10,15]]}},"URL":"https:\/\/doi.org\/10.11613\/bm.2026.030501","relation":{},"ISSN":["1846-7482","1330-0962"],"issn-type":[{"value":"1846-7482","type":"electronic"},{"value":"1330-0962","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10,15]]}}}